Most medical device companies misread their first few wins.
A respected physician tries the device. A pilot gets approved. A founder spends months coordinating internal stakeholders and eventually closes the deal. It looks like momentum. Leadership starts hiring, the board is encouraged, and the plan calls for replicating that motion across the next twenty accounts.
Then growth slows. Pilots stop converting. Approved hospitals do not ramp. The commercial team insists the market is interested, but adoption stays thin.
This is where most medtech CEOs discover an adoption system problem dressed up as a sales problem. And the gap between those two is where a lot of promising medical device companies quietly lose a year of growth.
Here is the short version of how to think about it. The full playbook goes deeper on each section and includes realistic scenarios across bariatric surgery, diagnostic imaging, cardiac monitoring, wound care, and robotic surgical platforms.
Click here to access the full playbook
Early Traction Is Not a Scalable Commercial Mode
The first ten customers are almost always carried by unusual energy. A founder who knows the clinical problem cold. A physician advocate willing to fight internal battles. A hospital willing to experiment. Those conditions rarely repeat at scale.
What most CEOs miss is that early wins hide the structural gaps that matter later: no repeatable stakeholder map, no codified buying path, no playbook for post-approval activation. Replicating founder-led deals is not a growth strategy. What’s needed is engineering these deals into a repeatable, scalable system that includes a clear stakeholder map, a standardized buying path, and a structured post-approval activation process.
Hospital Buying Is a Coordination Problem, Not a Persuasion Problem
Device companies often treat hospital adoption as a clinical sales motion. In reality, adoption moves through physicians, department leaders, nursing, procurement, value analysis committees, and finance. Each of them is evaluating a different kind of risk.
The biggest mistake here is assuming the clinical buyer and the economic buyer are the same person. They almost never are. A surgeon may love the device and still have zero interest in carrying it through committee review, supply chain objections, and budget prioritization. Knowing who owns each role inside the account is more predictive of adoption than any clinical demo.
Your Value Story Has to Survive Leaving the Physician’s Office
Most value propositions hold up well with a clinical champion and fall apart the moment procurement, VAC, or finance gets involved. Broad claims like “improves outcomes” and “supports efficiency” invite scrutiny instead of closing it.
A defensible value story is specific. It defines exactly which patients benefit, under what conditions, compared to what alternative, and with what operational or financial consequence for the hospital. Hospitals can live with an incomplete evidence base if the company is honest about what is proven and what still requires local validation. They have no patience for overreach.
Entry Strategy Determines Whether the Account Can Scale
Most companies enter accounts too broadly. They get a surgeon interested and immediately start talking about enterprise adoption. The hospital sees risk, pilots stall, and expansion becomes an uphill battle.
The better move is to choose a narrow, high-credibility starting point: one physician group, one procedure type, one patient segment where the fit is undeniable. The best wedge gets you in through a path that can actually expand, not the one that gets you in fastest.
Approval Is Not Adoption
This is the most expensive mistake in medtech. The hospital approves the device, contracting closes, leadership marks the account as won, and six months later usage is shallow.
Hospitals do not adopt because a contract exists. They adopt when clinicians use the device often enough for it to become normal. Real usage requires three types of champions (clinical, operational, and administrative), a written activation plan with named owners and utilization milestones, and active management of friction during the first case window. Leaving launch to an informal handoff is how approved accounts become dormant line items.
You Cannot Scale Without a Commercial Operating System
At some point, hospital adoption stops being an account problem and becomes an operating model problem. The company has a few wins, but founder involvement is the bottleneck, reps rely on individual style, and forecasting tracks activity instead of adoption.
What works at ten accounts breaks at fifty. Leadership needs a model that connects qualification, stakeholder progression, launch activation, and expansion, measured by adoption metrics like time to first use, repeat use rate, and expansion within live accounts. Pipeline volume alone is the wrong diagnostic tool for an adoption problem.
The 30-Day Leadership Reset
If adoption is underperforming, more pressure on the pipeline will not fix it. More reps will not fix it. More pilots will not fix it.
What works is a focused reset. Audit reality honestly. Tighten account qualification and pilot entry criteria. Rebuild the first-90-day launch motion. Put the right metrics in front of leadership. The companies that scale do not wait until growth fully stalls. They use the moment of uneven performance to tighten the model before inefficiency hardens into culture.
Get the Full Playbook
The e-book version of this piece covers each of these seven areas in depth. It includes stakeholder maps, pilot design frameworks, first-90-day activation templates, and the full commercial operating model, along with realistic scenarios from five different device categories.
Download Scaling Hospital Adoption: A Playbook for Medical Device Companies
Frequently Asked Questions
1. Why do medical device companies stall after early traction?
Most medical device companies stall because early wins were founder-led or carried by a single physician advocate, and that motion does not scale. The commercial model never gets codified into a repeatable system that addresses the full hospital buying process, including procurement, value analysis, and post-approval activation.
2. What is the difference between approval and adoption in medtech?
Approval means the hospital has cleared the device for purchase. Adoption means clinicians are using it consistently, with trained staff, reliable supply access, and growing utilization. Many medical device companies treat these as the same thing and discover too late that approved accounts can remain dormant for months.
3. Who makes purchasing decisions for medical devices in hospitals?
Hospital device purchasing decisions involve multiple stakeholders: physicians, department and service line leaders, nursing and operations, supply chain and procurement, value analysis committees, and finance. Each has different priorities and risk tolerances. The clinical buyer is rarely the same person as the economic buyer, which is one of the most common reasons deals stall.
4. What is a value analysis committee and how does it affect medical device sales?
A value analysis committee (VAC) is the internal hospital group that reviews new medical devices for clinical evidence, cost impact, workflow implications, and alignment with existing formulary. VAC review is where many device deals stall because companies arrive with enthusiasm instead of a defensible case that addresses clinical, operational, and economic concerns together.
5. How do you scale hospital adoption for a medical device company?
Scaling hospital adoption requires a commercial operating model that connects account qualification, stakeholder progression, launch activation, and expansion management. Companies that scale stop measuring success by contracts signed and start measuring it by time to first use, repeat use rate, and expansion within live systems.
6. Why do medical device pilots fail to convert?
Most medical device pilots fail to convert because they are structured as loose evaluations instead of controlled adoption decisions. A pilot that works has a defined use case, a named internal owner, operational clarity on training and supply, explicit decision criteria, a review date, and a pre-agreed conversion path if the pilot succeeds.
